EverHint Signal — Momentum Swing: Aggressive Momentum — December 10, 2025
What This Signal Is (Quick)
This scanner identifies the most aggressive momentum plays in the market—stocks showing the triple threat: high momentum + high volume + extreme volatility. These are not for the faint of heart.
The Setup: A stock breaking out or consolidating near resistance with:
- Volume 2.0x+ average (institutional confirmation)
- Volatility 50%+ annualized (high risk, high reward)
- Strong momentum near or at 52-week highs
This is pure momentum acceleration. When this scanner fires, it's catching stocks in the middle of explosive moves with institutions piling in. The risk: volatility cuts both ways—big gains come with big drawdowns. The reward: catching parabolic moves early.
Key Criteria:
- Volume thrust: 2.0x+ (institutions are buying)
- Volatility: 50%+ annualized (massive daily swings)
- Momentum: Strong rate of change across multiple timeframes
- Holding Period: 1-4 weeks (swing trading, not day trading)
This is experimental and only for aggressive traders who can handle 10-20% intraday swings without panic selling. If you need to sleep at night, this is not your strategy.
How We Ranked Today (Reader Version)
Signals are ranked by composite quality score (0-100 scale), which weighs:
- Rate of change momentum (10, 21, 63 days)
- Relative strength vs S&P 500
- Volume thrust magnitude
- Proximity to 52-week high
Higher scores indicate cleaner, higher-quality breakouts. We've overlaid:
- Insider Net (USD): Net insider buying/selling over 90 days. Positive = insiders buying volatility (bullish). Negative = insiders selling (bearish divergence).
- Days → Earnings: Proximity to earnings. < 30 days = catalyst potential but event risk.
- Vol Thrust: How much above average volume. Higher = stronger institutional conviction.
Important: These signals are for educational use and back-testing. This is an experimental scanner, not financial advice. High volatility = high risk. Position size accordingly.
🔥 Aggressive Momentum Signals (2 Signals)
Triple threat: high momentum + high volume + extreme volatility.
| Rank | Ticker | Company | Sector | Last ($) | Vol Thrust | % of 52W High | Volatility | Score | Market Cap | Insider Net (USD) | Days → Earnings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MRUS | Merus N.V. | Healthcare | 96.78 | 2.11x | 100.0% | 62.7% | 30 | $7.3B | -$796K | 78 |
| 2 | PRO | PROS Holdings | Technology | 23.25 | 3.23x | 100.0% | 70.7% | 0 | $1.1B | $0 | 57 |
Field Notes:
- Score: MRUS scores 30 (higher quality). PRO at 0 (lower confirmation but extreme volume).
- Vol Thrust: PRO leads at 3.23x (223% above average volume)—absolutely massive institutional buying. MRUS at 2.11x (111% above average). Both well above 2.0x threshold.
- % of 52W High: Both at exactly 100%—printing fresh all-time highs today.
- Volatility: PRO at 70.7% annualized (expect 4-5% daily swings). MRUS at 62.7% (expect 3-4% daily swings). Both extreme.
- Insider Net: MRUS -$796K (VP Controller sold $796K on Nov 25). PRO shows $0 (no P/S transactions in dataset).
- Days to Earnings: MRUS reports in 78 days (clean runway). PRO in 57 days (clean runway).
- Market Cap: MRUS $7.3B (mid-cap biotech), PRO $1.1B (small-cap SaaS).
Volatility Interpretation:
- 62.7% volatility (MRUS) = Expected daily move: ±3.9% ($3.78/day swing)
- 70.7% volatility (PRO) = Expected daily move: ±4.4% ($1.02/day swing)
These are not stable, safe stocks. These are rocket ships that can crash just as fast as they launch.
Recent Headlines (Last 3 Days)
MRUS (Merus N.V.):
- No major recent news in dataset.
- Stock at fresh all-time high of $96.78.
- Insider selling: VP Controller Shuman sold $796K at $95.92 on Nov 25.
PRO (PROS Holdings):
- No major recent news in dataset.
- Stock at fresh all-time high of $23.25.
- CEO Cotten exercised options and paid taxes (standard activity) Dec 2.
Vlad's Take (EverHint)
Today delivered just 2 aggressive momentum signals—but quality over quantity. When this scanner fires on only a couple names, it means the market isn't in full-blown melt-up mode. These are isolated pockets of extreme momentum, not broad-based froth.
Market Backdrop: S&P 500 +0.78%, Nasdaq +0.50%, Dow +1.02%—solid green across the board. VIX at 15.77 (low volatility environment for the broader market). Russell 2000 +1.39% (strong small-cap performance). Treasury yields flat at 4.19%, Bitcoin $92.6K, gold +0.44%. This is a risk-on environment, which supports momentum plays.
The Aggressive Momentum Thesis:
This strategy is about concentration risk. You're betting that a handful of stocks will deliver outsized returns. The tradeoff: you're taking outsized risk. Here's what we have:
PRO (PROS Holdings) — The Standout:
- 3.23x volume thrust is off the charts. This is the 10th highest volume thrust I've seen across all strategies today.
- 70.7% annualized volatility means this stock can swing $1+ per day. That's 4.4% daily range.
- 100% of 52-week high—fresh breakout happening right now.
- Small-cap SaaS company at $1.1B market cap. Thin float, easy to move.
- No insider selling in the P/S dataset (neutral to bullish).
The Risk: PRO is a $23 stock with 70% volatility. If momentum fails, this drops to $20 in days. If it continues, $27-30 is in play. This is a binary bet.
MRUS (Merus N.V.) — The Biotech Rocket:
- 2.11x volume thrust, clean breakout.
- 62.7% volatility—biotech stocks are inherently volatile, and this is above-average even for the sector.
- $7.3B market cap—mid-cap with more stability than PRO, but still high risk.
- -$796K insider selling from VP Controller in Nov. Not a huge red flag (single insider, small amount), but worth noting.
The Risk: Biotech names can gap down 20% on trial failures or FDA news. MRUS is at all-time highs, which means any disappointment = sharp reversal.
Trading Strategy for Aggressive Momentum:
-
Position sizing is EVERYTHING: With 60-70% volatility, you cannot size these like normal stocks. Max 1-2% of portfolio per signal. A 3% position in a 70% volatility stock = sleepless nights.
-
Stop placement: Set stops 8-10% below entry. With this much volatility, tight stops (3-5%) will get stopped out on normal intraday noise. Give the trade room to breathe, but cap your downside.
-
Profit targets: Look for 15-25% gains. Don't get greedy. These moves are fast but short-lived. Take profits on strength, let a small runner go if you want.
-
Time horizon: 1-4 weeks max. Momentum fades. If the stock consolidates for more than a week, reassess.
-
Entry timing: Don't chase today's close. Let the stock prove the breakout tomorrow. If it holds above today's low and volume remains elevated, enter. If it gaps down or volume dies, walk away.
-
Volatility drag: High volatility kills compounding. A stock that swings ±5% daily but ends flat over a week has destroyed option premium and shaken out weak hands. Be patient.
Sector Context:
- Healthcare (1): MRUS — biotech momentum
- Technology (1): PRO — SaaS momentum
No sector concentration. These are idiosyncratic plays, not sector rotations.
Why Only 2 Signals?
This is actually a good thing. When aggressive momentum scanners fire on 20+ stocks, it's usually a market top (everyone chasing). Two signals suggest:
- Selectivity — Only the most extreme setups qualify
- Quality over noise — These are real breakouts, not froth
- Lower market-wide mania — We're not in a bubble (yet)
Final Warning:
Aggressive momentum is not for everyone. If you:
- Can't handle seeing a position down 10% intraday
- Don't have experience trading volatile small-caps
- Are using retirement funds or can't afford to lose
...then skip this strategy entirely. Stick to pullbacks, SMA crosses, or EMA crossovers. This is the highest-risk strategy we publish.
But if you're an experienced trader with proper risk management, these setups can deliver 20-30% gains in 2-4 weeks. Just know the cost: high stress, high volatility, and the real possibility of -15% drawdowns before the move pays off.
🔥 If this breakdown was useful, feel free to like, share, or subscribe. Every bit of support matters.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/